Inotiv Inc reports results for the quarter ended June 30 - Earnings Summary

• Inotiv Inc NOTV reported a quarterly adjusted loss of 51 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-1.00. The mean expectation of three analysts for the quarter was for a loss of 51 cents per share. Wall Street expected results to range from -52 cents to -51 cents per share.

• Revenue rose 23.5% to $130.68 million from a year ago; analysts expected $127.05 million.

• Inotiv Inc's reported EPS for the quarter was a loss of 51 cents​.

• The company reported a quarterly loss of $17.58 million.

• Inotiv Inc shares had risen by 14.0% this quarter and lost 49.9% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Inotiv Inc is $5.00, about 56.2% above its last closing price of $2.19

This summary was machine generated from LSEG data August 7 at 12:54 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)